



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	99995	Guo Min Bi Yan Fang a.k.a. Xanthium & Astragalus Chronic Sinus Formula
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Sun Herbal Pty Ltd	
<b>Postal Address</b>	Unit 5/25 Garema Cct, Kingsgrove, NSW, 2208 Australia	
<b>ARTG Start Date</b>	3/03/2004	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1. Guo Min Bi Yan Fang a.k.a. Xanthium & Astragalus Chronic Sinus Formula

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	12/04/2018
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

Traditionally used in Chinese medicine to clear/dry/drain/eliminate/resolve dampness

Traditionally used in Chinese medicine to stabilise Exterior

Traditionally used in Chinese medicine to engender Fluid

Traditionally used in Chinese medicine to dispel/expel/disperse/clear external/exogenous heat

Traditionally used in Chinese medicine to tonify/nourish/strengthen/replenish Qi

Traditionally used in Chinese medicine to tonify/nourish/strengthen/replenish/fortify/invigorate spleen

Traditionally used in Chinese medicine to enrich/nourish/tonify/fortify/strengthen kidneys

Traditionally used in Chinese medicine to dispel/expel/extinguish/disperse/clear exogenous wind

Traditionally used in Chinese medicine to calm/soothe/nourish the liver

Traditionally used in Chinese medicine to unblock/clear nasal passages

### Indication Requirements

If TCM terminology is used on medicine label, label statement: Talk to a TCM practitioner/health professional if you are unsure if this medicine is right for you.

Product presentation must not imply or refer to disease in any body organ.

Product presentation must not imply or refer to liver disease, such as cirrhosis, hepatitis.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to kidney disease.

### Standard Indications

No Standard Indications included on Record



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

**Specific Indications**

No Specific Indications included on Record

**Warnings**

If symptoms persist consult your healthcare practitioner (or words to that effect).  
For practitioner dispensing only.

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>Angelica dahurica root Extract dry concentrate</b>	<b>20.4 mg</b>
Equivalent: Angelica dahurica (Dry)	122.4 mg
<b>Astragalus membranaceus root Extract dry concentrate</b>	<b>27 mg</b>
Equivalent: Astragalus membranaceus (Dry)	162 mg
<b>Atractylodes lancea rhizome Extract dry concentrate</b>	<b>19.8 mg</b>
Equivalent: Atractylodes lancea (Dry)	118.8 mg
<b>Atractylodes macrocephala rhizome Extract dry concentrate</b>	<b>22.5 mg</b>
Equivalent: Atractylodes macrocephala (Dry)	135 mg
<b>Ledebouriella seseloides root Extract dry concentrate</b>	<b>20.4 mg</b>
Equivalent: Ledebouriella seseloides (Dry)	122.4 mg
<b>Lycium chinense fruit Extract dry concentrate</b>	<b>22.5 mg</b>
Equivalent: Lycium chinense (Dry)	135 mg
<b>Magnolia liliflora flower bud Extract dry concentrate</b>	<b>20.4 mg</b>
Equivalent: Magnolia liliflora (Dry)	122.4 mg
<b>Mentha haplocalyx leaf Extract dry concentrate</b>	<b>20.4 mg</b>
Equivalent: Mentha haplocalyx (Dry)	122.4 mg
<b>Morus alba fruit Extract dry concentrate</b>	<b>22.5 mg</b>
Equivalent: Morus alba (Dry)	135 mg
<b>Pseudostellaria heterophylla root Extract dry concentrate</b>	<b>20.4 mg</b>
Equivalent: Pseudostellaria heterophylla (Dry)	122.4 mg
<b>Pueraria lobata root Extract dry concentrate</b>	<b>20.4 mg</b>
Equivalent: Pueraria lobata (Dry)	122.4 mg
<b>Rehmannia glutinosa root Extract dry concentrate</b>	<b>22.5 mg</b>
Equivalent: Rehmannia glutinosa (Dry)	135 mg
<b>Scutellaria baicalensis root Extract dry concentrate</b>	<b>20.4 mg</b>
Equivalent: Scutellaria baicalensis (Dry)	122.4 mg
<b>Xanthium sibiricum fruit Extract dry concentrate</b>	<b>20.4 mg</b>
Equivalent: Xanthium sibiricum (Dry)	122.4 mg

**Other Ingredients (Excipients)**

hydrolysed gelatin

titanium dioxide

Public Summary



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

---

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary